Bristol's Lagging OTC Growth Leads To Accelerated Divestiture Talks
This article was originally published in The Pink Sheet Daily
Executive Summary
A lack of foreseeable growth may precipitate the imminent sale of Bristol-Myers Squibb's line of OTCs